The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Open accessAbstract
Background In France, the combination hydroxychloroquine (HCQ) and azithromycin (AZ) is used in the treatment of COVID-19. Methods We retrospectively report on 1061 SARS-CoV-2 positive tested patients treated for at least three days with the following regimen: HCQ (200 mg three times daily for ten days) + AZ (500 mg on day 1 followed by 250 mg daily for the next four days). Outcomes were death, clinical worsening (transfer to ICU, and >10 day hospitalization) and viral shedding persistence (>10 days). Results A total of 1061 patients were included in this analysis (46.4% male, mean age 43.6 years – range 14–95 years). Good clinical outcome and virological cure were obtained in 973 patients within 10 days (91.7%). Prolonged viral carriage was observed in 47 patients (4.4%) and was associated to a higher viral load at diagnosis (p < .001) but viral culture was negative at day 10. All but one, were PCR-cleared at day 15. A poor clinical outcome (PClinO) was observed for 46 patients (4.3%) and 8 died (0.75%) (74–95 years old). All deaths resulted from respiratory failure and not from cardiac toxicity. Five patients are still hospitalized (98.7% of patients cured so far). PClinO was associated with older age (OR 1.11), severity of illness at admission (OR 10.05) and low HCQ serum concentration. PClinO was independently associated with the use of selective beta-blocking agents and angiotensin II receptor blockers (p < .05). A total of 2.3% of patients reported mild adverse events (gastrointestinal or skin symptoms, headache, insomnia and transient blurred vision). Conclusion Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with a very low fatality rate in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., et al. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.105949 · Cited by 5,288
Self-citationRetractedZhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Nextstrain: real-time tracking of pathogen evolution
Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154
Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa237 · Cited by 2,662
Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020) · Cell Discovery · doi:10.1038/s41421-020-0156-0 · Cited by 2,070
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,390
Tang, W., Cao, Z., Han, M., Wang, Z., Chen, J., Sun, W., Wu, Y., Xiao, W., Liu, S., Chen, E., et al. (2020) · BMJ · doi:10.1136/bmj.m1849 · Cited by 1,135
Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., Zhuang, R., Hu, B., & Zhang, Z. (2020) · medRxiv · doi:10.1101/2020.03.22.20040758 · Cited by 847
La Scola, B., Le Bideau, M., Andreani, J., Hoang, V. T., Grimaldier, C., Colson, P., Gautret, P., & Raoult, D. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03913-9 · Cited by 811
Self-citation
Cited by
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022926 · Cited by 1,265
From Diagnosis to Treatment: Recent Advances in Patient-Friendly Biosensors and Implantable Devices
Li, P., Lee, G.-H., Kim, S. Y., Kwon, S. Y., Kim, H.-R., & Park, S. (2021) · ACS Nano · doi:10.1021/acsnano.0c06688 · Cited by 359
Butler, C. C., Dorward, J., Yu, L.-M., Gbinigie, O., Hayward, G., Saville, B. R., Van Hecke, O., Berry, N., Detry, M., Saunders, C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00461-x · Cited by 298
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
Fajgenbaum, D. C., Khor, J. S., Gorzewski, A., Tamakloe, M.-A., Powers, V., Kakkis, J. J., Repasky, M., Taylor, A., Beschloss, A., Hernandez-Miyares, L., et al. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00303-8 · Cited by 52
Caldeira, D., Alves, M., Gouveia e Melo, R., Silvério António, P., Cunha, N., Nunes-Ferreira, A., Prada, L., Costa, J., & Pinto, F. J. (2020) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2020.100627 · Cited by 35
Metadata
- Authors
- Million, M., Lagier, J.-C., Gautret, P., Colson, P., Fournier, P.-E., Amrane, S., Hocquart, M., Mailhe, M., Esteves-Vieira, V., Doudier, B., Aubry, C., Correard, F., Giraud-Gatineau, A., Roussel, Y., Berenger, C., Cassir, N., Seng, P., Zandotti, C., Dhiver, C., Ravaux, I., Tomei, C., Eldin, C., Tissot-Dupont, H., Honoré, S., Stein, A., Jacquier, A., Deharo, J.-C., Chabrière, E., Levasseur, A., Fenollar, F., Rolain, J.-M., Obadia, Y., Brouqui, P., Drancourt, M., La Scola, B., Parola, P., & Raoult, D.
- Venue
- Travel Medicine and Infectious Disease
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 35
- Pages
- 101738
- ISSN
- 1477-8939 (ISSN-L)
- OpenAlex
- W3023911418
- Cited by
- 469
- References
- 31
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. https://app.cochat.ai/papers/10.1016/j.tmaid.2020.101738
- The paper
- Million, M., Lagier, J.-C., Gautret, P., Colson, P., Fournier, P.-E., Amrane, S., Hocquart, M., Mailhe, M., Esteves-Vieira, V., Doudier, B., Aubry, C., Correard, F., Giraud-Gatineau, A., Roussel, Y., Berenger, C., Cassir, N., Seng, P., Zandotti, C., Dhiver, C., . . . Raoult, D. (2020). Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Medicine and Infectious Disease. https://doi.org/10.1016/j.tmaid.2020.101738
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.